<DOC>
	<DOCNO>NCT01859351</DOCNO>
	<brief_summary>The purpose study test safety escalate dos novel PI3K inhibitor WX-037 explore effectiveness combination WX-554 target mitogen activate protein kinase ( MEK1 MEK2 ) . Preclinical evidence indicate two novel compound could provide target inhibition pathway block tumour growth .</brief_summary>
	<brief_title>Phase I Study WX-037 Alone Combination With WX-554 Solid Tumours</brief_title>
	<detailed_description />
	<criteria>Patients advance , metastatic and/or progressive solid tumor effective standard therapy available ( part 2 addition patient PI3K pathway deregulate ) Evaluable measurable disease Has normal organ function ; great 2 ECOG performance scale Negative hCG test woman childbearing potential History diabetes require daily medication history grade 3 fast hyperglycemia Patients major surgery , radiotherapy , immunotherapy within 4 week start study Clinical significant , unresolved toxicity previous anticancer therapy Patients previously receive MEK inhibitor ( combination part ) Presence active gastrointestinal disease condition interfere significantly absorption , distribution , metabolism , excretion drug Known medical history retinal vein occlusion , intraocular pressure great 21 mm Hg patient consider risk retinal vein thrombosis ( combination part ) Known HIV positivity active hepatitis B C infection History clinically significant cardiac condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>